Article Information
Volume 12, Issue 2, pp. 151-161
PubMed
Published By
Print ISSN
Online ISSN
History
- Received May 14, 2012
- Revision received December 13, 2012
- Accepted December 17, 2012
- Published first December 27, 2012.
Article Versions
- Previous version (December 27, 2012 - 14:39).
- Previous version (January 31, 2013 - 14:04).
- You are viewing the most recent version of this article.
Copyright & Usage
©2012 American Association for Cancer Research.
Author Information
- Stefan Hart1,
- Veronica Novotny-Diermayr1,
- Kee Chuan Goh1,
- Meredith Williams1,
- Yong Cheng Tan1,
- Lai Chun Ong1,
- Albert Cheong1,
- Bee Kheng Ng1,
- Chithra Amalini1,
- Babita Madan1,
- Harish Nagaraj1,
- Ramesh Jayaraman1,
- Khalid M. Pasha1,
- Kantharaj Ethirajulu1,
- Wee Joo Chng2,3,
- Nurulhuda Mustafa2,
- Boon Cher Goh2,
- Cyril Benes4,
- Ultan McDermott5,
- Mathew Garnett5,
- Brian Dymock1, and
- Jeanette M. Wood1
- Authors' Affiliations: 1S*BIO Pte Ltd.; 2Cancer Science Institute of Singapore, National University of Singapore; 3Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; 4Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and 5Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Corresponding Author:
Stefan Hart, S*BIO Pte Ltd., 1 Science Park Road, #05-09 The Capricorn, Singapore 117528, Singapore. Phone: 65-6645-3412; Fax: 65-6225-4654; E-mail: stefan.sbio{at}gmail.com
February 2013
Volume 12, Issue 2
Volume 12, Issue 2
VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer
Permalink:
Jump to section
Advertisement